ASCO GI 2024 | SWOG S2107: encorafenib + cetuximab ± nivolumab in BRAFV600E mCRC (previously treated, MSS)

Van K. Morris, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the prospective Phase II clinical trial SWOG S2107 (NCT05308446) for patients with previously treated microsatellite stable (MSS), BRAFV600E metastatic colorectal cancer (mCRC). In this trial (NCT05308446), participants are randomized into two arms: the experimental treatment arm (encorafenib + cetuximab + nivolumab) or the standard treatment arm (encorafenib + cetuximab). The primary endpoint is progression-free survival (PFS), with secondary endpoints including overall survival, best overall response, duration of response, and safety/tolerability. The hypothesis is that the addition of nivolumab to the treatment regimen will improve PFS for participants with MSS, BRAFV600E mCRC. As of September 2023, 37 of the planned 75 participants have been enrolled. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.